Please login to the form below

Not currently logged in
Email:
Password:

ivacaftor

This page shows the latest ivacaftor news and features for those working in and with pharma, biotech and healthcare.

Vertex gains EU approval for earlier Orkambi use

Vertex gains EU approval for earlier Orkambi use

Orkambi is a combination of lumacaftor and ivacaftor, which together targets the lack of CFTR proteins in CF patients.

Latest news

More from news
Approximately 6 fully matching, plus 23 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics